ArticleCancer medicine2026
Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant-Eligible and Ineligible Acute Myeloid Leukemia.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysozyme-induced nephropathy is a complication of chronic myelomonocytic leukemia and acute myeloid leukemia (AML). Few studies have discussed the association between blood lysozyme levels at AML onset and AML prognosis, which this study aimed to address. A total of 166 AML patients (72 transplant-eligible and 94 transplant-ineligible cases) undergoing chemotherapy at our hospital with recorded serum lysozyme levels were retrospectively included between March 2012 and March 2024. The median age, creatinine, and serum lysozyme at diagnosis were 65 (22-86) years, 0.85 mg/dL (0.43-3.56), and 16.4 μg/mL (0.3-560.0), respectively. Hematopoietic stem cell transplantation was performed in 43.4% of all patients. At initial diagnosis, the lysozyme and creatinine levels were positively correlated (the Spearman rank correlation coefficient: +0.516, p < 0.05). Using ROC analysis, the optimal serum lysozyme cutoff values for predicting AKI (KDIGO > 0) at AML onset were determined to be 22.4 μg/mL (AUC, 0.89: 95% CI: 0.847-0.951). The two-year overall survival (OS) did not differ significantly between patients with lysozyme < 22.4 μg/mL and patients with lysozyme ≥ 22.4 μg/mL (two-year OS, 39.5% vs. 42.2% [95% CI, 29.2%-49.6% vs. 29.8%-54.1%]; p = 0.862). The same trend was observed in the transplantation group. After remission induction, most patients with high-lysozyme levels showed creatinine level recovery (AML onset: median 1.15 mg/dL, 1 month later: median 0.72 mg/dL, 3 months later: median 0.65 mg/dL). The effect of lysozyme levels on prognosis is limited because renal function recovers in many patients with high-lysozyme levels after chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.